Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies

David R. Lally*, Anat Loewenstein, Jennifer J. Arnold, Yit C. Yang, Kinfemichael Gedif, Catherine Best, Hersh Patel, Ramin Tadayoni, Jeffrey S. Heier

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies'. Together they form a unique fingerprint.

Medicine & Life Sciences